SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is facing significant volatility as investors weigh the impact of potential memory-compression algorithms against the reality of long-term AI demand. While some in the community are aggressively buying the dip, others are citing macro concerns related to the conflict in the Middle East and energy costs, leading to a clash between institutional selling and retail bottom-fishing.

Federal National Mortgage Association is a government-sponsored company, which engages in the provision of liquidity for purchases of homes and financing of multifamily rental housing and refinancing existing mortgages. It operates through the Single-Family and Multifamily segments. The Single-Family segment offers liquidity to the mortgage market and increases the availability and affordability of housing for single families. The Multifamily segment includes guaranty fees on mortgages and on multifamily mortgage loans. The company was founded in 1938 and is headquartered in Washington, DC.

Federal National Mortgage Association

Fannie Mae is capturing market attention as prominent investors like Bill Ackman and Michael Burry reinforce their bullish thesis on the stock's potential for a significant valuation uplift. The community is actively debating the timing of a potential release from government conservatorship, with many viewing recent volatility as a strategic opportunity to build positions amid ongoing speculation about political catalysts and policy shifts.

MP Materials Corp. engages in the production and marketing of rare earth specialty materials. It operates through the Materials and Magnetics segments. The Materials segment focuses on the operation of Mountain Pass, which produces refined rare earth oxides and related products, as well as rare earth concentrate products. The Magnetics segment is involved in the operation of Independence Facility, where the company began production of magnetic precursor products. The company was founded by James Henry Litinsky and Michael Rosenthal in 2017 and is headquartered in Las Vegas, NV.

MP Materials Corporation

MP Materials is under intense focus as investors weigh upcoming earnings alongside the company's long-term strategic pivot toward domestic magnet manufacturing and its partnership with the Department of Defense. Community sentiment remains polarized, with bullish investors highlighting the stock's role in U.S. supply chain independence and recent facility expansion, while others express frustration over recent price volatility and high-volume selling pressure.

Applied Digital Corporation

Applied Digital is experiencing intense volatility as investors weigh the company's long-term potential in AI infrastructure against macro-driven sell-offs linked to geopolitical tensions and debt concerns. While the community remains divided between those panic-selling and those adding to their positions, sentiment is heavily focused on the anticipation of new hyperscaler lease announcements as the primary catalyst for a recovery.

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvana Co. is facing significant volatility following a board-approved 5-for-1 forward stock split, a move investors are interpreting as an attempt to boost retail accessibility and liquidity amid skepticism over the company's long-term fundamentals. The community remains deeply divided, with vocal bears pointing to concerns over subprime loan exposure and potential accounting practices, while some bulls advocate for a rebound based on historical momentum and speculative positioning.

Maul Coin

Maul Coin is generating buzz as the community rallies around its recent launch and actively pushes for social media visibility to drive momentum following earlier volatility.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy Corp

Bloom Energy is currently rallying toward new highs as the market increasingly views its on-site power solutions as a critical 'bring-your-own-power' fix for AI data centers facing grid capacity constraints. While some investors are cautioning about potential overvaluation after a rapid run-up, the community remains heavily focused on the company's massive backlog and the strategic importance of its fuel cell technology in the ongoing AI infrastructure buildout.

Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Endoscopy, Urology, and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.

Boston Scientific Corp.

Boston Scientific is currently trending as investors weigh the company's long-term growth driven by innovations in electrophysiology and the WATCHMAN FLX device against recent market volatility and analyst concerns regarding valuation premiums. The community is actively debating the stock's stability, with many highlighting the stock as a prime candidate for accumulation on dips while others express frustration over recent price action.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is facing intense market volatility as investors weigh the company's long-term foundry expansion against broader geopolitical instability and semiconductor supply chain constraints. While some traders are capitalizing on rapid price swings and rumors of potential fab deals, the community remains divided between those betting on a manufacturing-led turnaround and those bracing for further downside amid macroeconomic uncertainty.

Free Bird

Free Bird is gaining traction as community members highlight the asset's structural consistency and market resilience amid broader cryptocurrency volatility. Enthusiasts are actively rallying behind the token, framing participation as a display of patriotic sentiment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Viridian Therapeutics Shares Jump as REVEAL-1 Phase 3 Hits Primary Endpoint in Thyroid Eye Disease

Viridian Therapeutics (NASDAQ:VRDN) reported top-line results from its REVEAL-1 Phase III clinical trial evaluating subcutaneous (SC) elegrobart (ELE) in patients with active thyroid eye disease...

Why Is Viridian Therapeutics Stock Falling Monday?

Viridian (VRDN) shares plunge 38% premarket despite positive Phase 3 TED trial data. Analysts weigh in on elegrobart's market viability.read more...

Futures, Gold Jump As Yields Fall Despite Surging Oil As Recession Fears Surpass Inflation Concerns

Futures, Gold Jump As Yields Fall Despite Surging Oil As Recession Fears Surpass Inflation Concerns Futures are higher despite continued Iran war escalation which pushed Brent higher by around 2...

<ul class="summary-bullets"><li>Viridian stated that the REVEAL-1 trial showed strong results, meeting its main goal and a key secondary goal at week 24 as measured by eye bulging.</li><li>The company stated that Elegrobart reduced eye bulging by about 54% in the four-week regimen and by 63% in the eight-week regimen, compared with roughly 18% on placebo.</li><li>Viridian stated that topline results from REVEAL-2, the second Phase 3 trial evaluating Elegrobart in patients with chronic thyroid eye disease, are expected in the second quarter of 2026.</li></ul>Viridian Therapeutics Inc. (VRDN) shares tanked more than 41% in Monday’s pre-market trade after the company announced results from its Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease.Viridian stated that the REVEAL-1 trial of Elegrobart met its primary endpoint of proptosis responder rate (PRR) with a highly statistically significant treatment effect in the four-week dosing regimen.However, the company stated that while Elegrobart was generally well tolerated in the four and eight-week dosing regimens, the phase 3 trial showed low rates of hearing impairment.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/VRDN">Viridian Therapeutics</a> trended in the ‘bullish’ territory with message volumes at ‘high’ levels at the time of writing.<h2 class="st-heading-2">What Did The Trial Reveal?</h2>Viridian stated that the REVEAL-1 trial showed strong results, meeting its main goal and a key secondary goal at week 24 as measured by eye bulging. The study also tested a different dosing schedule (every 8 weeks) versus placebo and examined other important outcomes.The company stated that Elegrobart reduced eye bulging by about 54% in the four-week regimen and by 63% in the eight-week regimen, compared with roughly 18% on placebo.However, Elegrobart showed only a slight improvement over placebo in the Clinical Activity Score (CAS), a measure of inflammation and disease activity.Viridian’s results showed that the CAS reduction to 0 or 1 was 57% in the four-week regimen and 69% in the eight-week regimen, compared with 50% in the placebo group.The company said that all complaints of adverse events in both regimens were reports of tinnitus, none of which were associated with hearing reduction.<h2 class="st-heading-2">Viridian Says Elegrobart On Track For BLA Submission In 2027</h2>The company stated that topline results from REVEAL-2, the second Phase 3 trial evaluating Elegrobart in patients with chronic thyroid eye disease, are expected in the second quarter (Q2) of 2026.Following this, Viridian plans to submit a Biologics License Application (BLA) to the U.S. FDA in Q1 2027. A BLA is a formal request submitted to the U.S. Food and Drug Administration (FDA) asking for approval to sell a biologic drug.<a href="https://stocktwits.com/symbol/VRDN">VRDN stock</a> is down 12% year-to-date, but up 87% over the past 12 months. The SPDR S&amp;P Biotech ETF (XBI) is up 40% over the past 12 months, while the iShares Russell 2000 ETF (IWM) is up 19%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/roma-stock-soars-100m-share-repurchase-program/cZERVIhRIZs">ROMA Stock Shot Up 10% Today – Everything To Know About Its Gigantic Share Repurchase Program</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Trading digital board showing the data on global stock market crash. | Image source: Getty Images

VRDN Stock Plummeted 41% Pre-Market Today — What Did Its Phase 3 Active Thyroid Eye Disease Trial Reveal?

Viridian stated that while Elegrobart was generally well tolerated in the four and eight-week dosing regimens, the phase 3 trial showed low rates of hearing impairment.

Equity

Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL1 Clinical Trial in Active Thyroid Eye Disease

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today announced positive topline data from the elegrobart REVEAL-1 phase 3 clinical trial in patients with...

Hudson Bay Capital Management LP Raises Stake in Viridian Therapeutics, Inc. $VRDN

Hudson Bay Capital Management LP raised its stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 46.6% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 175,251 shares of the company's...

This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know

Key PointsKynam Capital sold 2,957,386 shares of Viridian Therapeutics in the fourth quarter; the estimated trade size was $81.11 million based on quarterly average pricing...

Commodore Capital LP Cuts Stake in Viridian Therapeutics, Inc. $VRDN

Commodore Capital LP reduced its holdings in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 34.4% during the third quarter, according to its most recent disclosure with the...

Viridian Therapeutics, Inc. $VRDN Stock Holdings Reduced by Rosalind Advisors Inc.

Rosalind Advisors Inc. lowered its position in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 14.3% during the third quarter, according to its most recent Form 13F filing with the SEC...

Wedbush Reaffirms Outperform Rating for Viridian Therapeutics (NASDAQ:VRDN)

Wedbush reissued an "outperform" rating and issued a $44.00 price target on shares of Viridian Therapeutics in a research report on Wednesday...

Viridian Therapeutics, Inc. is a biopharmaceutical company that develops medicines for autoimmune and rare diseases. It uses antibody discovery and protein engineering to create new therapies. The company is advancing late-stage IGF-1R therapies for thyroid eye disease (TED) and developing a potential TSHR-targeted treatment for TED and Graves’ disease. In addition, it is developing FcRn inhibitors, including VRDN-006 and VRDN-008, for multiple autoimmune diseases. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

Viridian Therapeutics Inc

Fred Wilson - Union Square Ventures

Abigail Johnson - Fidelity

Jim Cramer - Media Personality

Josh Brown - Ritholtz Wealth Management

A lifetime achievement for industry titans. This honor is reserved for an individual whose groundbreaking contributions have shaped the investing landscape and how we engage with the markets.

Stocktwits

Stocktwits Polls

Investors are weighing the positive clinical trial endpoint results against the surprising and sharp sell-off in share price.

Technically focused investors are analyzing support levels and sentiment as the stock experiences extreme volatility after data release.

Current Price	$18.20
Prev Close	$27.39
Open	$16.86
Dividend Yield	0.00%
50-Day Moving Average	$29.82
Beta	1.11
Avg. Volume	1.44M
PE Ratio	-7.20

52-Week High	$34.29
52-Week Low	$9.90
Market Capitalization	$2.8B
EPS (Annual)	-$3.32
Price to Book	4.73
Revenue Per Employee	$281,146.83

VRDN
Viridian Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest VRDN News

VRDNViridian Therapeutics Inc